Bacteriophage virus-like particle vaccines against flavivirus non-structural protein 1
AssigneeUNM Rainforest Innovations
InventorsKATHRYN MARIE FRIETZE, NICOLE WARNER
Life of this patent
Estimating the term…
Abstract
The present invention is directed to virus-like particles (VLPs) which display immunogenic peptides of Flavivirus non-structural Protein 1 (NS1) derived from Dengue Virus (DENY), immunogenic compositions and vaccines against Flavivirus infection and related methods of immunizing and/or vaccinating subjects against Flavivirus, especially Dengue infections. The VLPs according to the present invention comprise polypeptide subunits of Dengue NS 1 protein which has been conjugated to the surface of a VLP as described herein, often a VLP derived from a Qbeta (Pβ) or AP205 bacteriophage.
Claims49
A composition comprising:
- (a) a virus-like particle (VLP) comprising a bacteriophage coat protein;
- and (b) at least one immunogenic peptide;
- wherein said immunogenic peptide is conjugated onto said virus-like particle, and wherein said immunogenic peptide is between 5 and 17 contiguous amino acids derived from a conserved or non-conserved region of NS1 peptide of dengue virus (DENV).
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
A composition comprising:
- (a) a virus-like particle (VLP) comprising 94180 Qβ bacteriophage single chain coat proteins which self-assemble into said VLP;
- and (b) at least one immunogenic peptide;
- wherein said immunogenic peptide is conjugated onto said VLP, wherein said immunogenic peptide is between 5 and 17 contiguous amino acids of amino acid sequences SEQ ID Nos:
- 1-10 and 14-22 and said immunogenic peptide is conjugated to said VLP through a linker molecule comprising a crosslinker covalently bonded to an oligopeptide, wherein said crosslinker is (Succinimidyl-6-[β-maleimidopropionamido]hexanoate) (SMPH) and said oligopeptide is GGGC of SEQ ID NO:
- 13 wherein said N-terminal glycine residue of said oligopeptide is covalently bonded to the carboxyl terminus of said immunogenic peptide and said carboxyl terminal cysteinyl residue is covalently bonded to the crosslinker and the crosslinker is also bonded to a lysine residue on the VLP.
(canceled)
(canceled)
(canceled)
(canceled)
49-62. (canceled)
Dependencies are inferred from the claim text.